| Bioactivity | Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease[1][2]. |
| Target | CXCL10 (IP-10). |
| Name | Eldelumab |
| CAS | 946414-98-8 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gupta RK, et al. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. PLoS One. 2021 Sep 28;16(9):e0257784. [2]. Asquith DL, et al. Targeting cell migration in rheumatoid arthritis. Curr Opin Rheumatol. 2015 Mar;27(2):204-11. |